Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta)

Kara B. Duffy, Balmiki Ray, Debomoy Lahiri, Edward M. Tilmont, Gregory P. Tinkler, Richard L. Herbert, Nigel H. Greig, Donald K. Ingram, Mary Ann Ottinger, Julie A. Mattison

Research output: Contribution to journalArticle

Abstract

The degeneration in the locus coeruleus associated with Alzheimer's disease suggests an involvement of the noradrenergic system in the disease pathogenesis. The role of depleted norepinephrine was tested in adult and aged rhesus macaques to develop a potential model for testing Alzheimer's disease interventions. Monkeys were injected with the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) or vehicle at 0, 3, and 6 months; brains were harvested at 9 months. Reduced norepinephrine in the locus coeruleus was accompanied by decreased dopamine β-hydroxylase staining and increased amyloid-β load in the aged group, and the proportion of potentially toxic amyloid-β 42 peptide was increased. Immunohistochemistry revealed no effects on microglia or astrocytes. DSP4 treatment altered amyloid processing, but these changes were not associated with the induction of chronic neuroinflammation. These findings suggest norepinephrine deregulation is an essential component of a nonhuman primate model of Alzheimer's disease, but further refinement is necessary.

Original languageEnglish (US)
Pages (from-to)115-126
Number of pages12
JournalJournal of Alzheimer's Disease
Volume68
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Macaca mulatta
Amyloid
Norepinephrine
Alzheimer Disease
Locus Coeruleus
Pathology
Poisons
Neurotoxins
Microglia
Mixed Function Oxygenases
Astrocytes
Primates
Haplorhini
Dopamine
Therapeutics
Immunohistochemistry
Staining and Labeling
Peptides
Brain
DSP 4

Keywords

  • Alzheimer's disease
  • DSP4
  • locus coeruleus
  • neurotoxin
  • nonhuman primate
  • norepinephrine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta). / Duffy, Kara B.; Ray, Balmiki; Lahiri, Debomoy; Tilmont, Edward M.; Tinkler, Gregory P.; Herbert, Richard L.; Greig, Nigel H.; Ingram, Donald K.; Ottinger, Mary Ann; Mattison, Julie A.

In: Journal of Alzheimer's Disease, Vol. 68, No. 1, 01.01.2019, p. 115-126.

Research output: Contribution to journalArticle

Duffy, KB, Ray, B, Lahiri, D, Tilmont, EM, Tinkler, GP, Herbert, RL, Greig, NH, Ingram, DK, Ottinger, MA & Mattison, JA 2019, 'Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta)', Journal of Alzheimer's Disease, vol. 68, no. 1, pp. 115-126. https://doi.org/10.3233/JAD-180487
Duffy, Kara B. ; Ray, Balmiki ; Lahiri, Debomoy ; Tilmont, Edward M. ; Tinkler, Gregory P. ; Herbert, Richard L. ; Greig, Nigel H. ; Ingram, Donald K. ; Ottinger, Mary Ann ; Mattison, Julie A. / Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta). In: Journal of Alzheimer's Disease. 2019 ; Vol. 68, No. 1. pp. 115-126.
@article{21279abe22fe454287eae25c41bfadee,
title = "Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta)",
abstract = "The degeneration in the locus coeruleus associated with Alzheimer's disease suggests an involvement of the noradrenergic system in the disease pathogenesis. The role of depleted norepinephrine was tested in adult and aged rhesus macaques to develop a potential model for testing Alzheimer's disease interventions. Monkeys were injected with the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) or vehicle at 0, 3, and 6 months; brains were harvested at 9 months. Reduced norepinephrine in the locus coeruleus was accompanied by decreased dopamine β-hydroxylase staining and increased amyloid-β load in the aged group, and the proportion of potentially toxic amyloid-β 42 peptide was increased. Immunohistochemistry revealed no effects on microglia or astrocytes. DSP4 treatment altered amyloid processing, but these changes were not associated with the induction of chronic neuroinflammation. These findings suggest norepinephrine deregulation is an essential component of a nonhuman primate model of Alzheimer's disease, but further refinement is necessary.",
keywords = "Alzheimer's disease, DSP4, locus coeruleus, neurotoxin, nonhuman primate, norepinephrine",
author = "Duffy, {Kara B.} and Balmiki Ray and Debomoy Lahiri and Tilmont, {Edward M.} and Tinkler, {Gregory P.} and Herbert, {Richard L.} and Greig, {Nigel H.} and Ingram, {Donald K.} and Ottinger, {Mary Ann} and Mattison, {Julie A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3233/JAD-180487",
language = "English (US)",
volume = "68",
pages = "115--126",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta)

AU - Duffy, Kara B.

AU - Ray, Balmiki

AU - Lahiri, Debomoy

AU - Tilmont, Edward M.

AU - Tinkler, Gregory P.

AU - Herbert, Richard L.

AU - Greig, Nigel H.

AU - Ingram, Donald K.

AU - Ottinger, Mary Ann

AU - Mattison, Julie A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The degeneration in the locus coeruleus associated with Alzheimer's disease suggests an involvement of the noradrenergic system in the disease pathogenesis. The role of depleted norepinephrine was tested in adult and aged rhesus macaques to develop a potential model for testing Alzheimer's disease interventions. Monkeys were injected with the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) or vehicle at 0, 3, and 6 months; brains were harvested at 9 months. Reduced norepinephrine in the locus coeruleus was accompanied by decreased dopamine β-hydroxylase staining and increased amyloid-β load in the aged group, and the proportion of potentially toxic amyloid-β 42 peptide was increased. Immunohistochemistry revealed no effects on microglia or astrocytes. DSP4 treatment altered amyloid processing, but these changes were not associated with the induction of chronic neuroinflammation. These findings suggest norepinephrine deregulation is an essential component of a nonhuman primate model of Alzheimer's disease, but further refinement is necessary.

AB - The degeneration in the locus coeruleus associated with Alzheimer's disease suggests an involvement of the noradrenergic system in the disease pathogenesis. The role of depleted norepinephrine was tested in adult and aged rhesus macaques to develop a potential model for testing Alzheimer's disease interventions. Monkeys were injected with the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) or vehicle at 0, 3, and 6 months; brains were harvested at 9 months. Reduced norepinephrine in the locus coeruleus was accompanied by decreased dopamine β-hydroxylase staining and increased amyloid-β load in the aged group, and the proportion of potentially toxic amyloid-β 42 peptide was increased. Immunohistochemistry revealed no effects on microglia or astrocytes. DSP4 treatment altered amyloid processing, but these changes were not associated with the induction of chronic neuroinflammation. These findings suggest norepinephrine deregulation is an essential component of a nonhuman primate model of Alzheimer's disease, but further refinement is necessary.

KW - Alzheimer's disease

KW - DSP4

KW - locus coeruleus

KW - neurotoxin

KW - nonhuman primate

KW - norepinephrine

UR - http://www.scopus.com/inward/record.url?scp=85062883742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062883742&partnerID=8YFLogxK

U2 - 10.3233/JAD-180487

DO - 10.3233/JAD-180487

M3 - Article

C2 - 30689563

AN - SCOPUS:85062883742

VL - 68

SP - 115

EP - 126

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -